Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen

Wenqing Yan,Juan Du,Yanzhi Du,Honglei Pu,Shuyan Liu,Jie He,Ji Zhang,Jian Hou
DOI: https://doi.org/10.1016/j.leukres.2016.10.010
IF: 3.715
2016-01-01
Leukemia Research
Abstract:•Fenretinide is capable of eradicating myeloma SP and MP cells, but not BMMCs.•Fenretinide induced apoptosis was linked to the rapid generation of ROS.•Fenretinide has more effect on SP cells combined with bortezomib and dexamethasone.•Fenretinide is a promising therapeutic agent in MM treatment.
What problem does this paper attempt to address?